COMPASS Pathways launches proposed public offering
COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the launch of a proposed public offering of 4,000,000 American Depositary Shares each representing one ordinary share. Each of the ADSs is being offered by COMPASS. COMPASS expects to grant the underwriters a 30-day option to purchase up to an additional 600,000 …
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the launch of a proposed public offering of 4,000,000 American Depositary Shares (“ADSs”), each representing one ordinary share.
New-york
United-states
Edgewood
United-kingdom
London
City-of
America
Tracy-cheung
Stephen-schultz
Broadridge-financial-solutions
Cantor-fitzgerald-co
Berenberg-capital-markets
(0)
Study concludes that psilocybin findings should be explored further in larger studies
London, UK, April 15, 2021(NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD).
The study was designed and conducted by a research team at Imperial College London, using COMPASS s COMP360 psilocybin.
This was an exploratory, randomised, double-blind clinical study. Its aim was to compare the efficacy and mechanisms of action of psilocybin with a six-week course of escitalopram, a selective serotonin reuptake inhibitor (SSRI), for MDD.
The study included 59 participants; 30 were randomly assigned to the psilocybin arm, and 29 to the escitalopram arm. Participants in the psilocybin arm received two doses of 25mg psilocybin three weeks apart, with psychological support delivered prior to, during and after each psilocybin administration, plus six weeks of daily placebo caps
New-york
United-states
United-kingdom
London
City-of
America
Kostenloser-wertpapierhandel
Tracy-cheung
George-goldsmith
Stephen-schultz
Exchange-commission
Linkedin
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
New England Journal of Medicine publishes exploratory study showing signals of positive .
COMPASS Pathfinder Ltd.April 15, 2021 GMT
London, UK, April 15, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the New England Journal of Medicine (NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD).
ADVERTISEMENT
The study was designed and conducted by a research team at Imperial College London, using COMPASS’s COMP360 psilocybin.
New-york
United-states
United-kingdom
London
City-of
America
Tracy-cheung
George-goldsmith
Stephen-schultz
Exchange-commission
Linkedin
Imperial-college-london
New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the New England Journal of Medicine yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder . The study was designed and conducted by a research …
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the New England Journal of Medicine (NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive dis
New-york
United-states
United-kingdom
London
City-of
America
Tracy-cheung
George-goldsmith
Stephen-schultz
Exchange-commission
Linkedin
Imperial-college-london
vimarsana © 2020. All Rights Reserved.